Filtered By:
Source: Circulation
Condition: Bleeding
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 151 results found since Jan 2013.
Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study.
CONCLUSIONS: -In patients with DM, continued thienopyridine beyond 1-year after coronary stenting is associated with reduced risk of MI, although this benefit is attenuated when compared with patients without DM. Clinical Trial Registration Information-ClinicalTrials.gov. Identifier: NCT00977938.
PMID: 26994121 [PubMed - as supplied by publisher]
Source: Circulation - March 18, 2016 Category: Cardiology Authors: Meredith IT, Tanguay JF, Kereiakes DJ, Cutlip DE, Yeh RW, Garratt KN, Lee DP, Steg PG, Weaver WD, Holmes DR, Brindis RG, Trebacz J, Massaro JM, Hsieh WH, Mauri L, DAPT Study Investigators Tags: Circulation Source Type: research
Gait Speed Predicts 30-Day Mortality Following Transcatheter Aortic Valve Replacement: Results From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry™.
CONCLUSIONS: -Gait speed is independently associated with 30-day mortality following TAVR. Identification of frail patients with the slowest gait speeds facilitates pre-procedural evaluation and anticipation of a higher level of post-procedural care. Clinical Trial Registration Information-ClinicalTrials.gov. Identifier: NCT01737528.
PMID: 26920495 [PubMed - as supplied by publisher]
Source: Circulation - February 26, 2016 Category: Cardiology Authors: Alfredsson J, Stebbins A, Brennan JM, Matsouaka R, Afilalo J, Peterson ED, Vemulapalli S, Rumsfeld JS, Shahian D, Mack MJ, Alexander KP Tags: Circulation Source Type: research
Polypharmacy and the Efficacy and Safety of Rivaroxaban versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
CONCLUSIONS: -In a population of patients with AF, two-thirds were on ≥5 medications. Increasing medication use was associated with higher risk of bleeding but not stroke. Rivaroxaban was tolerated across complex patients on multiple medications. Clinical Trial Registration Information-ClinicalTrials.gov. Identifier: NCT00403767.
PMID: 26673560 [PubMed - as supplied by publisher]
Source: Circulation - December 16, 2015 Category: Cardiology Authors: Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR Tags: Circulation Source Type: research
The Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients with Prior Myocardial Infarction and no History of Stroke or TIA: Results from TRA 2°P-TIMI 50.
CONCLUSIONS: -Vorapaxar reduced cardiovascular death, MI, or stroke in stable patients with a history of prior MI, whether treated concomitantly with a thienopyridine or not. The relative risk of moderate or severe bleeding was similarly increased irrespective of thienopyridine use. Clinical Trial Registration Information-http://www.clinicaltrials.gov. Identifier: NCT00526474.
PMID: 26338971 [PubMed - as supplied by publisher]
Source: Circulation - September 3, 2015 Category: Cardiology Authors: Bohula EA, Aylward PE, Bonaca MP, Corbalan RL, Kiss RG, Murphy SA, Scirica BM, White H, Braunwald E, Morrow DA Tags: Circulation Source Type: research
Recanalization Therapies in Acute Ischemic Stroke Patients: Impact of Prior Treatment with Novel Oral Anticoagulants on Bleeding Complications and Outcome - A Pilot Study.
CONCLUSIONS: -IVT/IAT in selected patients with ischemic stroke under NOAC treatment has a safety profile similar to both, IVT/IAT in patients on subtherapeutic VKA-treatment or in those without prior anticoagulation. However, further prospective studies are needed, including the impact of specific coagulation tests.
PMID: 26232277 [PubMed - as supplied by publisher]
Source: Circulation - July 31, 2015 Category: Cardiology Authors: Seiffge DJ, Van Hooff RJ, Nolte CH, Béjot Y, Turc G, Ikenberg B, Berge E, Persike M, Dequatre-Ponchelle N, Strbian D, Pfeilschifter W, Zini A, Tveiten A, Næss H, Michel P, Sztajzel R, Luft A, Gensicke H, Traenka C, Hert L, Scheitz JF, De Marchis G, Bona Tags: Circulation Source Type: research
Apixaban Compared with Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the ARISTOTLE Trial.
CONCLUSIONS: -More than a quarter of the patients in ARISTOTLE with "nonvalvular" atrial fibrillation had moderate or severe valvular heart disease. There was no evidence of a differential effect of apixaban over warfarin in reducing stroke or systemic embolism, causing less bleeding, and reducing death in patients with and without valvular heart disease. Clinical Trial Registration Information-clinicaltrials.gov. Identifier: NCT00412984.
PMID: 26106009 [PubMed - as supplied by publisher]
Source: Circulation - June 23, 2015 Category: Cardiology Authors: Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH Tags: Circulation Source Type: research
Restarting Anticoagulant Treatment After Intracranial Haemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality and Bleeding: A Nationwide Cohort Study.
CONCLUSIONS: -Oral anticoagulant treatment was associated with a significant reduction in ischemic stroke/all-cause mortality rates, supporting oral anticoagulant treatment reintroduction post-intracranial haemorrhage as feasible. Future trials are encouraged to guide clinical practice in these patients.
PMID: 26059010 [PubMed - as supplied by publisher]
Source: Circulation - June 9, 2015 Category: Cardiology Authors: Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY Tags: Circulation Source Type: research
Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis.
CONCLUSIONS: -DOACs demonstrated at least equal efficacy to VKA in managing thrombotic risks in the elderly however bleeding patterns were distinct. In particular, dabigatran was associated with a higher risk of gastrointestinal bleeding than VKA. Insufficient published data for apixaban, edoxaban and rivaroxaban indicates further work is needed to clarify their bleeding risks in the elderly.
PMID: 25995317 [PubMed - as supplied by publisher]
Source: Circulation - May 20, 2015 Category: Cardiology Authors: Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M Tags: Circulation Source Type: research
Vorapaxar in Patients With Diabetes and Prior MI: Findings from the TRA 2°P-TIMI 50 Trial.
CONCLUSIONS: -In patients with prior MI and DM, the addition of vorapaxar to standard therapy significantly reduced the risk of major vascular events with greater potential for absolute benefit in this group at high risk of recurrent ischemic events. Clinical Trial Registration Information-www.clinicaltrials.gov. Identifier: NCT00526474.
PMID: 25681464 [PubMed - as supplied by publisher]
Source: Circulation - February 13, 2015 Category: Cardiology Authors: Cavender MA, Scirica BM, Bonaca MP, Angiolillo DJ, Dalby AJ, Dellborg M, Morais J, Murphy SA, Oude Ophius T, Tendera M, Braunwald E, Morrow DA Tags: Circulation Source Type: research
Letter by Weinrauch and Barkoudah Regarding Article, "Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation. Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry".
PMID: 25645616 [PubMed - in process]
Source: Circulation - February 3, 2015 Category: Cardiology Authors: Weinrauch LA, Barkoudah E Tags: Circulation Source Type: research
Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis.
CONCLUSIONS: -More dialysis patients are being started on dabigatran and rivaroxaban, even when their use is contraindicated and there are no studies to support the benefits outweigh the risks of these drugs in ESRD.
PMID: 25595139 [PubMed - as supplied by publisher]
Source: Circulation - January 16, 2015 Category: Cardiology Authors: Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW Tags: Circulation Source Type: research
Response to letter regarding article, "warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis".
PMID: 25539527 [PubMed - in process]
Source: Circulation - December 23, 2014 Category: Cardiology Authors: Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L Tags: Circulation Source Type: research
Letter by qureshi et Al regarding article, "warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis".
PMID: 25539526 [PubMed - in process]
Source: Circulation - December 23, 2014 Category: Cardiology Authors: Qureshi W, Alirhayim Z, Khalid F Tags: Circulation Source Type: research
Use and Outcomes Associated with Bridging During Anticoagulation Interruptions in Patients with Atrial Fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
CONCLUSIONS: -Bridging anticoagulation is used in one-quarter of anticoagulation interruptions and is associated with higher risk for bleeding and adverse events. These data do not support the use of routine bridging and additional data are needed to identify best practices around anticoagulation interruptions. Clinical Trial Registration Information-clinicaltrials.gov. Identifier: NCT01165710.
PMID: 25499873 [PubMed - as supplied by publisher]
Source: Circulation - December 12, 2014 Category: Cardiology Authors: Steinberg BA, Peterson ED, Kim S, Thomas L, Gersh BJ, Fonarow GC, Kowey PR, Mahaffey KW, Sherwood MW, Chang P, Piccini JP, Ansell J, on behalf of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patie Tags: Circulation Source Type: research
Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate.
CONCLUSIONS: -The 4F-PCC dose-dependently reversed the effects of edoxaban (60 mg), with complete reversal of bleeding duration and endogenous thrombin potential and partial reversal of prothrombin time following 50 IU/kg. Edoxaban alone and in combination with 4F-PCC was safe and well tolerated in these healthy subjects. A dose of 50 IU/kg 4F-PCC may be suitable for reversing edoxaban anticoagulation. Clinical Trial Registration-URL: http://clinicaltrials.gov. Unique identifier: NCT02047565.
PMID: 25403645 [PubMed - as supplied by publisher]
Source: Circulation - November 17, 2014 Category: Cardiology Authors: Zahir H, Brown KS, Vandell A, Desai M, Maa JF, Dishy V, Lomeli B, Feussner A, Feng W, He L, Grosso MA, Lanz HJ, Antman EM Tags: Circulation Source Type: research
